D. Boral Capital Maintains Buy Rating for UroGen Pharma with $25 Price Target

D. Boral Capital maintains a Buy rating for UroGen Pharma with a price target of $25.00. Analyst Jason Kolbert reiterated the current price target, which remains unchanged from the prior evaluation. UroGen Pharma specializes in solutions for urothelial and specialty cancers, with its flagship product Jelmyto and investigational candidate UGN-102 targeting non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer.

UroGen Pharma Ltd., a biotechnology company specializing in solutions for urothelial and specialty cancers, has received a Buy rating from D. Boral Capital with a price target of $25.00. The analyst, Jason Kolbert, reiterated this target, which remains unchanged from the prior evaluation [1].

UroGen Pharma's flagship product, Jelmyto, and its investigational candidate, UGN-102, are designed to target non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The company's focus on innovative technologies, such as its proprietary polymeric biocompatible reverse thermal gelation hydrogel technology, positions it as a leader in the field.

The company's lead product candidate, UGN-102, is currently in development for the treatment of several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). Additionally, UGN-301 is being developed for the treatment of high-grade NMIBC. These products are part of UroGen Pharma's broader strategy to improve the therapeutic profiles of existing drugs and develop new solutions for cancer treatment.

UroGen Pharma has several strategic partnerships that support its research and development efforts. These include a license agreement with Agenus Inc., a strategic research collaboration with MD Anderson, and a licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. These collaborations aim to enhance the company's capabilities and accelerate the development and commercialization of its products.

The company's stock has shown significant growth this year, with shares increasing by 77.9% from $10.65 at the beginning of 2025 to $18.95 as of the current date. However, the company's earnings have been negative, with a projected decrease in earnings growth for the coming year from ($3.12) to ($3.14) per share. The company's P/E ratio is -5.96, indicating that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Despite these challenges, UroGen Pharma continues to attract strong analyst interest, with 6 research reports in the past 90 days and a consensus rating of Buy. The company's high institutional ownership of 91.29% suggests strong market trust. However, the recent increase in short interest by 201.63% indicates a decrease in investor sentiment.

In summary, UroGen Pharma's innovative approach to cancer treatment and strategic partnerships position it as a promising player in the biotechnology sector. However, the company faces significant challenges, including negative earnings and a high short interest ratio. Investors should carefully consider these factors when evaluating the company's prospects.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/URGN/